In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Building a Comprehensive Real World Evidence Strategy
ICON’s Jim Carroll outlines how a fully integrated, multidisciplinary RWE model can save time, money and effort in study development and execution, for better commercial outcomes.
-
A Rare Journey: Managing the Regulatory Landscape
ICON contributes to this article in PharmaVOICE looking at efforts undertaken to progress the development ofrare disease drugs.
-
Adaptive Clinical Trial Designs Are Innovative
Article featuring commentary from Rolf Hvelmann and Parvin Fardipour on tackling theoperational challenges of adaptive trials.
-
Big Changes for EU Medical and In Vitro Diagnostic Device Regulations
In this new ACT article, Vicki Anastasi share details on how medical device manufacturers will be challenged to generate clinical data on safety, performance and any undesirable side effects under newMDR and IVDR regulations.
-
CROs and Next-Gen Drug Development
An article featuring commentary from Steve Cutler on thefuture of drug development.
-
Is There A Better Way To Value Asset Duration In Biopharma Deal-Making?
ICON’s Andy Smith discusses the role of duration in the valuation of early-stage biopharma assets in this In Vivo article.
-
Time Is Money
ICON’s Andy Smith discusses the role of duration in the valuation of early-stage biopharma assets in this In Vivo article.
-
Proving Real World Value
In the July/Aug 2017 issue of PME, Ramita Tandon discusses how to usereal world intelligenceto demonstrate drug efficacy and cost-effectiveness.
-
Domestic Research Enhancement Act Changing Clinical Trials Outsourcing
This article includes commentary from Steve Cutler on US healthcare policy and its effect onclinical trial outsourcing.
-
The Burden of Choice
Dr. Martin Lachs, Dr. Reinhard Eisebitt and Dr. Valerii Fedorov contribute to this article inClinical Oncologist Dailyon ICON's decision to invest in aCancer Moonshot project using quantum computing.
